Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prognosis bad
|
2 | 0.708 | 0.280 | 6 | 151627231 | intergenic variant | G/A | snv | 0.41 | 0.700 | 0 | ||||||||
Early-Stage Breast Carcinoma
|
7 | 0.708 | 0.280 | 6 | 151627231 | intergenic variant | G/A | snv | 0.41 | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||
ESTROGEN RESISTANCE
|
7 | 0.708 | 0.280 | 6 | 151627231 | intergenic variant | G/A | snv | 0.41 | 0.700 | 0 | ||||||||
Breast Fibrocystic Disease
|
12 | 0.708 | 0.280 | 6 | 151627231 | intergenic variant | G/A | snv | 0.41 | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||
Carcinoma of Male Breast
|
38 | 0.708 | 0.280 | 6 | 151627231 | intergenic variant | G/A | snv | 0.41 | 0.010 | 1.000 | 1 | 2013 | 2013 | |||||
estrogen receptor-negative breast cancer
|
40 | 0.708 | 0.280 | 6 | 151627231 | intergenic variant | G/A | snv | 0.41 | 0.020 | 1.000 | 2 | 2011 | 2014 | |||||
Malignant neoplasm of male breast
|
43 | 0.708 | 0.280 | 6 | 151627231 | intergenic variant | G/A | snv | 0.41 | 0.010 | 1.000 | 1 | 2013 | 2013 | |||||
Hyperlipidemia
|
83 | 0.708 | 0.280 | 6 | 151627231 | intergenic variant | G/A | snv | 0.41 | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||
Breast Cancer, Familial
|
91 | 0.708 | 0.280 | 6 | 151627231 | intergenic variant | G/A | snv | 0.41 | 0.010 | 1.000 | 1 | 2013 | 2013 | |||||
Triple-Negative Breast Carcinoma
|
96 | 0.708 | 0.280 | 6 | 151627231 | intergenic variant | G/A | snv | 0.41 | 0.010 | 1.000 | 1 | 2011 | 2011 | |||||
Triple Negative Breast Neoplasms
|
99 | 0.708 | 0.280 | 6 | 151627231 | intergenic variant | G/A | snv | 0.41 | 0.010 | 1.000 | 1 | 2011 | 2011 | |||||
Malignant neoplasm of endometrium
|
197 | 0.708 | 0.280 | 6 | 151627231 | intergenic variant | G/A | snv | 0.41 | 0.010 | 1.000 | 1 | 2011 | 2011 | |||||
Nasopharyngeal carcinoma
|
320 | 0.708 | 0.280 | 6 | 151627231 | intergenic variant | G/A | snv | 0.41 | 0.700 | 1.000 | 1 | 2010 | 2010 | |||||
Endometrial Carcinoma
|
326 | 0.708 | 0.280 | 6 | 151627231 | intergenic variant | G/A | snv | 0.41 | 0.010 | 1.000 | 1 | 2011 | 2011 | |||||
Carcinogenesis
|
355 | 0.708 | 0.280 | 6 | 151627231 | intergenic variant | G/A | snv | 0.41 | 0.010 | 1.000 | 1 | 2015 | 2015 | |||||
Bone Density
|
654 | 0.708 | 0.280 | 6 | 151627231 | intergenic variant | G/A | snv | 0.41 | 0.700 | 1.000 | 1 | 2009 | 2009 | |||||
Primary malignant neoplasm
|
1374 | 0.708 | 0.280 | 6 | 151627231 | intergenic variant | G/A | snv | 0.41 | 0.020 | 1.000 | 2 | 2013 | 2016 | |||||
Malignant Neoplasms
|
1641 | 0.708 | 0.280 | 6 | 151627231 | intergenic variant | G/A | snv | 0.41 | 0.020 | 1.000 | 2 | 2013 | 2016 | |||||
Neoplasms
|
1644 | 0.708 | 0.280 | 6 | 151627231 | intergenic variant | G/A | snv | 0.41 | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||
Breast Carcinoma
|
2793 | 0.708 | 0.280 | 6 | 151627231 | intergenic variant | G/A | snv | 0.41 | 0.900 | 1.000 | 28 | 2009 | 2019 | |||||
Malignant neoplasm of breast
|
3417 | 0.708 | 0.280 | 6 | 151627231 | intergenic variant | G/A | snv | 0.41 | 0.800 | 1.000 | 26 | 2009 | 2019 |